Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Journal of Clinical Oncology · 2021 · 2K citations · Full text

Pharmacy, Immunology, Oncology +17

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

X. Long Zheng, Sara K. Vesely, Spero R. Cataland et al. · Journal of Thrombosis and Haemostasis · 2020 · 393 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

Alexander Eggermont, Christian U. Blank, Mario Mandalà et al. · The Lancet Oncology · 2021 · 389 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Hematologic Complications of Immune Checkpoint Inhibitors

Elizabeth J. Davis, Joe‐Elie Salem, Arissa Young et al. · The Oncologist · 2019 · 176 citations · Full text

Medicine, Hematology, Pharmacology +17

Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes

Deirdra R. Terrell, Sara K. Vesely, Johanna A. Kremer Hovinga et al. · American Journal of Hematology · 2010 · 92 citations · Full text

Medicine, Hematology, Immunology +13